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Abstract
Mitochondrial complex I deficiency occurs in the substantia nigra of individuals with Parkinson’s disease. It is generally 
believed that this phenomenon is caused by accumulating mitochondrial DNA damage in neurons and that it contributes to 
the process of neurodegeneration. We hypothesized that if these theories are correct, complex I deficiency should extend 
beyond the substantia nigra to other affected brain regions in Parkinson’s disease and correlate tightly with neuronal mito-
chondrial DNA damage. To test our hypothesis, we employed a combination of semiquantitative immunohistochemical 
analyses, Western blot and activity measurements, to assess complex I quantity and function in multiple brain regions from 
an extensively characterized population-based cohort of idiopathic Parkinson’s disease (n = 18) and gender and age matched 
healthy controls (n = 11). Mitochondrial DNA was assessed in single neurons from the same areas by real-time PCR. Immu-
nohistochemistry showed that neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, including areas 
spared by the neurodegenerative process such as the cerebellum. Activity measurements in brain homogenate confirmed a 
moderate decrease of complex I function, whereas Western blot was less sensitive, detecting only a mild reduction, which 
did not reach statistical significance at the group level. With the exception of the substantia nigra, neuronal complex I loss 
showed no correlation with the load of somatic mitochondrial DNA damage. Interestingly, α-synuclein aggregation was less 
common in complex I deficient neurons in the substantia nigra. We show that neuronal complex I deficiency is a widespread 
phenomenon in the Parkinson’s disease brain which, contrary to mainstream theory, does not follow the anatomical distribu-
tion of neurodegeneration and is not associated with the neuronal load of mitochondrial DNA mutation. Our findings suggest 
that complex I deficiency in Parkinson’s disease can occur independently of mitochondrial DNA damage and may not have 
a pathogenic role in the neurodegenerative process.
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Introduction
Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder affecting 1.8% of the popu-
lation above the age of 65 years [11]. It is characterized 
by progressive motor dysfunction including bradykinesia, 
rigidity, resting tremor and postural instability. In addi-
tion, a number of non-motor symptoms occur, including 
autonomic dysfunction, dementia, depression and anxi-
ety. The pathological hallmark of PD is the degeneration 
of the dopaminergic neurons in the pars compacta of the 
substantia nigra (SNc) in the presence of α-synuclein 
immunoreactive neuronal inclusions collectively termed 
Lewy pathology. Other affected areas comprise multiple 
brainstem and cholinergic nuclei, the hippocampus and 
the neocortex. Neuropathologically spared regions include 
the striatum, cerebellum, thalamus, red nucleus and the 
pontine nuclei [12].
Although the etiology of PD is unknown, mitochon-
drial dysfunction has been associated with both familial 
and idiopathic forms of the disease. In the early 1980s, it 
was discovered that substances inhibiting complex I of the 
mitochondrial respiratory chain (MRC) cause nigrostriatal 
degeneration and parkinsonism [6, 22, 30]. Subsequently, 
evidence of complex I deficiency was shown in the SNc of 
individuals with idiopathic PD [25, 35]. While this phe-
nomenon has been consistently reproduced by multiple 
studies [17, 18, 23, 24, 34] its significance remains unde-
termined. It is unclear whether complex I deficiency in 
PD is a primary pathogenic event compromising neuronal 
integrity, an adaptive response to disease-related stress, 
or merely a symptom of end-stage dysfunction in termi-
nally ill neurons. The SNc, where this phenomenon has 
been best characterized, has already lost at least 60% of 
its dopaminergic neuronal population at symptom onset 
[9] and suffers end-stage neurodegeneration in the vast 
majority of autopsy-derived samples. Studies of other 
brain areas are both limited in number and show conflict-
ing results; while some experiments have found decreased 
complex I activity in frontal cortex homogenate from 
individuals with PD [19, 27] others showed no difference 
between individuals with PD and controls [18, 36]. One 
recent study found that complex I activity was decreased 
in prefrontal cortex homogenate from individuals with 
Parkinson’s disease dementia (PDD), but within normal 
range in non-demented PD individuals [14]. Complex I 
activity measurements and/or Western blot quantification 
in homogenized samples of the cerebellum and striatum 
have shown normal findings [18, 24, 25, 36]. Other brain 
areas remain unexplored.
We hypothesized that if complex I deficiency is actively 
involved in the neurodegenerative process of PD, it should 
not be limited to the SNc, but extend to other regions of 
the brain involved in the disease. To address this ques-
tion, we performed comprehensive, quantitative and func-
tional studies of the MRC in multiple brain regions from 
a population-based cohort of individuals with validated 
idiopathic PD and healthy controls. Our findings show that 
neuronal complex I quantity and function are decreased 
throughout the PD brain, including mildly affected areas 
and areas unaffected by neurodegeneration. Intriguingly, 
we find no correlation between complex I deficiency and 
mitochondrial DNA (mtDNA) damage, suggesting an 
alternative etiology.
Materials and methods
Patient cohorts and tissue samples
Brain tissue was available from individuals with idiopathic 
PD (n  =  18) and neurologically healthy controls (Ctrl 
n = 11). The individuals with PD were obtained from the 
Norwegian Park West study, a prospective population-based 
cohort that has been described in detail [2]. Individuals with 
PD fulfilled the National Institute of Neurological Disor-
ders and Stroke [15] and the UK Parkinson’s disease Society 
Brain Bank [43] diagnostic criteria for the disease at their 
final visit. Whole-exome sequencing had been performed 
on all patients using Roche-NimbleGen Sequence Capture 
EZ Exome v3 kit and paired-end 100nt sequencing on the 
Illumina HiSeq platform (unpublished material). To exclude 
monogenic cases, which could potentially confound our 
study, genes associated with familial parkinsonism (SNCA, 
LRRK2, VPS35, EIF4G1, DCTN1, CHCHD2, PARK2, 
PINK1, PARK7, ATP13A2, PLA2G6, FBXO7, COQ2, 
SLC6A3) were extracted and screened with no evidence of 
known pathogenic mutations. In addition, coverage analysis 
of the SNCA exons showed no evidence of copy number 
variation. Mitochondrial disease due to known nuclear gene 
mutations (e.g. POLG, TWNK, OPA1 or nuclear encoded 
respiratory subunits) was also excluded from the exome 
data. None of the study participants had clinical signs of 
mitochondrial disease. Controls had no known neurological 
disease and were matched for age and gender. Individuals 
with PD and controls had no history of mitochondrial disor-
der or use of medication known to influence mitochondrial 
function (Supplementary Table 1).
Brains were collected at autopsy and split sagittally along 
the corpus callosum. One hemisphere was fixed whole in 
formaldehyde and the other coronally sectioned and snap-
frozen in liquid nitrogen. All samples were collected using a 
standard technique and fixation time of ~ 2 weeks. There was 
no significant difference in post-mortem (PM) time (inde-
pendent t test, P = 0.06), age (independent t test, P = 0.17) 
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or gender (Chi-square test P > 0.96) between PD subjects 
and controls. Subject demographics and tissue availability 
are summarized in Table 1.
Immunohistochemistry
Immunohistochemistry (IHC) for mitochondrial markers was 
carried out on formalin-fixed, paraffin-embedded brain tissue 
from the following areas of individuals with PD and neuro-
logically healthy controls: prefrontal cortex, Brodmann areas 
8–9 (PD n = 14, Ctrl n = 6), hippocampus (PD n = 12, Ctrl 
n = 5), putamen (PD n = 14, Ctrl n = 5), cerebellum (PD 
n = 14, Ctrl n = 7), mesencephalon at the level of the third 
cranial nerve (PD n = 8, Ctrl n = 6) and basal pons at the 
level of the locus coeruleus (PD n = 12, Ctrl n = 5). Serial 
3 μm thick sections were stained with primary antibodies 
(all from Abcam) against complex I (NDUFB8, ab110242, 
dilution 1:300), complex II (anti-SDHA, ab14715, dilution 
1:4000), complex III (anti-UQCRC2, ab14745, dilution 
1:10,000), complex IV (COX-I, ab14705, dilution 1:10,000), 
complex V (ATP-synthase, ab14748, dilution 1:10,000), 
and the mitochondrial membrane marker porin (VDAC1, 
ab14734, dilution 1:10,000). We chose the NDUFB8 subu-
nit because it is central to complex I assembly and function 
[10, 39, 46] and has been widely used as a marker of the 
integrity of the complex [16, 40, 41]. Sections were depar-
affinised in Histoclear and rehydrated in graded ethanol. 
Antigen retrieval was performed in 1 mM EDTA at pH 8. 
The sections were blocked in 3% hydrogen peroxide in TBS 
(tris-buffered saline) and permeabilized in TBS containing 
0.1% Tween 20 (TBST). Incubation with primary antibody 
diluted in TBST was executed at 4 °C overnight. MACH4 
Universal HRP (horseradish peroxidase)-polymer (Biocare 
M4U534) and DAB (3′3-diaminobenzidine) chromogen kit 
(Biocare DB801) were used for visualization.
Double fluorescent immunohistochemistry was per-
formed for α-synuclein (clone KM51, NCL-L-ASYN, Leica, 
dilution 1:20) and complex I (NDUFS1, ab169540, Abcam, 
dilution 1:100) in the SNc (PD n = 4, Ctrl n = 1). Anti-
NDUFS1 was chosen here instead of anti-NDUFB8 because 
it produced better results (stronger signal) in immunofluo-
rescent staining. NDUFS1 is a core subunit considered 
essential for complex I function [5]. Sections were depar-
affinised in Histoclear and rehydrated in graded ethanol. 
Antigen retrieval was performed in 1 mM EDTA at pH 8. 
Sections were permeabilized in 1% Triton X-100 in TBS, 
and blocked in 3% normal goat serum in TBST. Incubation 
with primary antibody diluted in 3% normal goat serum in 
TBST was executed at 4 °C overnight. Secondary antibod-
ies (goat anti-rabbit IgG (Alexa Fluor 488, A11008), goat 
anti-mouse IgG1 (Alexa Fluor 594, A21125) and goat anti-
mouse IgG2b (Alexa Fluor 647, A21242); all from Invitro-
gen) were diluted in 3% normal goat serum in TBST for 1 h 
at room temperature. DAPI (Invitrogen) was used to visual-
ize the nucleus, and Sudan Black (Sigma Aldrich) was used 
to quench auto-fluorescence.
Immunohistochemistry analysis
IHC of sections stained with HRP-conjugated secondary 
antibodies was evaluated visually and quantitatively. First, 
high-resolution microphotographs were taken at 400× mag-
nification from randomly chosen locations of the following 
brain regions (the number of photographs taken per region 
and individual is given in parenthesis): prefrontal cortex 
(15), hippocampus (12; comprising three from each of CA4, 
CA3, CA2 and CA1), putamen (5), SNc (five from the pars 
compacta region), red nucleus (3), dentate nucleus (5), cer-
ebellar cortex (6), basis pontis (3). Analysis of the locus 
coeruleus was not possible due to severe degeneration in 
PD. All photographs were taken using a light microscope 
(Leica) equipped with a Zeiss AxioCam MRc5 camera and 
Zen 2011 software (Carl Zeiss MicroImaging GmbH, Jena, 
Germany) under standardized conditions.
For visual assessment, photographed areas were evalu-
ated by three investigators with expertise in mitochondrial 
staining and neuropathology (IF, CT, ML). For the quantita-
tive analyses, all neurons with a visible nucleolus were cut 
out from each of the photographed areas, and stacked on 
a uniform black background using Fiji v2.0.0 [37]. Next, 
the nucleus was cut out, and photomontages were made for 
each area including one unstained neuron from a negative 
control without primary antibody. The colour threshold of 
each montage was calibrated using the negative control to 
define absence of staining. Subsequently the number of posi-
tive cytoplasmic pixels (i.e. pixels showing colour satura-
tion above the level of the negative control) was counted 
and a ratio was made between the number of positive and 
total pixels of neuronal cytoplasm. Thus, the fraction of 
positively stained cytoplasm of each neuron (i.e. positively 
stained cytoplasmic area/total cytoplasmic area) was calcu-
lated. We termed this positive fractional cytoplasmic area 
(PFCA) (Fig. 1a–f). To ensure adequate sample size, we 
analysed a total of 1197 control and 2569 PD neurons. The 
number of neurons analysed from each individual and region 
are shown in Table 2.
The entire SNc was photographed at 200× magnification 
and photomontages of individual neurons were constructed 
as described above. Due to the presence of neuromelanin 
interfering with automated measurement procedures, the 
photomontages were evaluated visually by IHF, CD and KH. 
Investigators were blinded for disease group. A mean of the 
measurements from the three evaluators was used to deter-
mine the percentage of positive, intermediate and negative 
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Fig. 1  Determination of the positive fractional cytoplasmic area for 
semiquantitative IHC analysis. The positive fractional cytoplasmic 
area (PFCA), i.e. the area percentage of positive cytoplasmic staining, 
was determined as measure for expression of mitochondrial proteins 
as follows: Multiple microphotographs were taken at ×400 magni-
fication from each region. As an example, a single photograph from 
prefrontal cortex is shown (a). All neurons with a visible nucleolus 
(arrowheads in a) were cut out (b) and the background and nuclei 
removed leaving only the cytoplasm (c). Neurons from each area 
were combined into a single photomontage (d) including an unstained 
negative control as calibrator (*). Subsequently, the total cytoplasmic 
area (coloured red in e) and positively stained cytoplasmic area com-
pared to the unstained calibrator (coloured red in f) were measured 
and the ratio of positive to total cytoplasm was used to calculate the 
PFCA. Due to interference of neuromelanin, the substantia nigra was 
analysed visually from a montage including two negative (*) and two 
positive (**) controls (g). Dopaminergic neurons in the substantia 
nigra were categorised as negative, intermediate or positive. Scale 
bar: 50 µm
414 Acta Neuropathologica (2018) 135:409–425
1 3
415Acta Neuropathologica (2018) 135:409–425 
1 3
neurons (Fig. 1g). A total of 374 SNc dopaminergic neurons 
were evaluated in PD and 767 in controls.
Fluorescent immunohistochemistry for complex I and 
α-synuclein in the SNc was assessed using a Leica DMRBE 
fluorescence microscope and a Zeiss AxioCam MRm 
camera and Zen 2011 software (Carl Zeiss MicroImaging 
GmbH, Jena, Germany). A total of 123 dopaminergic SNc 
neurons were assessed from 13 microphotographs, taken at 
400× magnification, from each of 4 PD individuals. All neu-
romelanin containing neurons in the photographs were clas-
sified as complex I positive or negative, and Lewy pathology 
positive or negative. Evaluation was performed visually by 
IHF, CD and CT.
Complex I enzyme activity measurement
Approximately 100 mg of brain tissue from prefrontal cor-
tex (PD n = 7, Ctrl n = 6), striatum (PD n = 8, Ctrl n = 8), 
and cerebellar cortex (PD n = 9, Ctrl n = 7) were cut in 
small pieces and manually homogenized in five volumes 
of Medium A (0.32 M Sucrose, 10 mM Tris–HCl pH 7.4, 
1 mM EDTA). The homogenate was centrifuged at 800g 
for 5 min at 4 °C. The pellet was discarded and the super-
natant containing the enriched mitochondrial fraction was 
collected. NADH:Coenzyme  Q1 oxidoreductase activ-
ity was measured in a 96-well plate reader by measuring 
the decrease in absorbance at 340 nm wave-length, in the 
absence or presence of rotenone [20, 38]. Citrate synthase 
activity, an indicator of mitochondrial volume, was meas-
ured for normalization [20, 38].
Blue‑native gel electrophoresis 
and immunoblotting
1–1.5 mg of mitochondrial protein from prefrontal cortex 
(PD n = 11, Ctrl n = 11), striatum (PD n = 6, Ctrl n = 6), 
and cerebellar cortex (PD n = 8, Ctrl n = 2) were solubilized 
using 1.6 mg dodecyl-maltoside/mg protein to analyse com-
plex I by blue-native gel electrophoresis and Western blot as 
described [26, 33, 44]. 50 μg of mitochondrial protein was 
separated by electrophoresis and complexes I and II were 
immuno-visualised using anti-NDUFB8 (Abcam ab110242, 
dilution 1:1000) and anti-SDHB (Abcam ab14714, dilution 
1:1000), respectively.
Single neuron laser‑microdissection studies
Qualitative and quantitative mtDNA studies were per-
formed in a total of 1189 single laser-microdissected 
neurons from 20 µm thick sections of fresh-frozen tis-
sue, which had been stained with cresyl violet. The data 
from the SNc, cerebellum and frontal cortex have been 
described in detail in our previously published work using 
consistent subject ID’s [13]. To allow for a more com-
plete correlation with our complex I data, we expanded 
the experiment to include pyramidal neurons from the 
CA2 and CA3 area of the hippocampus (47 neurons from 
nine individuals with PD and 34 neurons from four con-
trols) and principal neurons of the putamen (72 neurons 
from nine individuals with PD and 65 neurons from eight 
controls). Total mtDNA copy number and the fraction 
of major arc deletion were determined using a duplex 
real-time PCR assay as previously described [13] in 7–12 
single neurons per brain region from each PD individual 
or control.
Statistical analysis
Comparison of neuronal staining levels (PFCA) between 
PD and controls was performed using linear mixed mod-
els analyses, to account for intraindividual random vari-
ability and interindividual variation in the number of 
analysed neurons per region. Subjects were specified as 
random effects and multiple mixed models were produced 
to assess the effect of disease state, sex, age of death, and 
PM-time on neuronal staining levels. These parameters 
were assessed in our models as fixed effects both indi-
vidually and in combinations. The error distribution was 
assumed normal, and solution to the mixed models was 
obtained using the maximum likelihood estimation method 
to determine if there were significant differences between 
the models. The likelihood ratio of different mixed models 
was sequentially tested using ANOVA. Model selection 
was based on the results from the ANOVA of model com-
parison together with visual inspection of the Akaike infor-
mation criterion (AIC). The mixed-effect model analyses 
were implemented using the “Linear and Nonlinear Mixed 
Effects Models” package in R (v3.3.0).
Complex I levels in the SNc were analysed by independ-
ent t test to compare the fraction of negative/positive or 
intermediate neurons in controls vs PD. The association 
between Lewy pathology and complex I state in the SNc 
was assessed by Pearson Chi-square test. Densitometric blot 
measurements in the prefrontal cortex and striatum were 
Fig. 2  Selective complex I deficiency in PD neurons. a MRC com-
plex IHC in the prefrontal cortex of a representative individual with 
PD and control (magnification ×400, scale bar 50  µm). Staining 
intensity is representative for all areas examined. b Mean neuronal 
staining levels per brain region for each MRC complex, expressed as 
PFCA (bars show SD). c Visual evaluation of the SNc. The fraction 
(%) of positively stained neurons for each complex is shown. Individ-
uals with PD have a higher fraction of complex I negative neurons. 
There is also a mild complex IV deficiency with increased levels of 
intermediate neurons, although negative neurons were not detected. 
Staining of the neuropil occurs with all MRC complexes as expected. 
Bars show SD. For columns with no bars, SD  =  0, i.e. all neurons 
were assessed as positive
◂
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compared by Mann–Whitney U test as these were not nor-
mally distributed. Statistical analysis of blot data from the 
cerebellum was not performed due to a small control sample 
size (n = 2). mtDNA data comparison was performed by 
linear mixed models. These analyses were carried out in 
SPSS version 22.0.0 and Prism version 7.0a. Data is pre-
sented as mean ± SD. A P < 0.05 was considered statisti-
cally significant in all analyses. Correlations with clinical 
parameters were not undertaken as the sample size did not 
provide sufficient power to draw definite conclusions.
Results
Widespread neuronal complex I deficiency in the PD 
brain
The demographic and clinical characteristics of the individu-
als with PD are summarized in Table 1. To characterize the 
type and distribution of MRC dysfunction in the PD, we first 
performed a pilot study of IHC on a randomly selected sub-
set of individuals with PD (n = 3) and controls (n = 3) from 
our cohorts. Sections from prefrontal cortex, hippocampus, 
putamen, pons, and SNc were stained for complexes I–V. 
Visual evaluation of the sections suggested that complex I 
was decreased in all areas in PD compared to the controls. 
No differences were detected for complexes II, III, IV and 
V, in any of the areas with the exception of the SNc where a 
mild complex IV deficiency was found (Fig. 2a).
To allow for accurate comparison between brain regions 
and individuals, and correlation with clinical variables in 
our cohort, we applied a standardized semiquantification 
method to calculate the positive fractional cytoplasmic 
area (PFCA, details in methods; Fig. 1). Quantification 
confirmed that individuals with PD had decreased neu-
ronal complex I staining in all areas, whereas complexes 
II–V stained similar to healthy controls (Fig. 2b).
To confirm and further characterize the anatomical dis-
tribution of neuronal complex I changes in a larger sample 
we performed quantitative analyses of complex I staining 
in our entire cohort of individuals with PD (n = 17) and 
controls (n = 7). Linear mixed model analyses showed 
no significant impact for sex, age of death or PM-time 
on staining levels. Individuals with PD had significantly 
decreased neuronal complex I staining in pyramidal 
neurons of the prefrontal cortex (PD 53.9 ± 32.9%, Ctrl 
84.0 ± 13.9%, P = 0.023), pyramidal neurons of the hip-
pocampus CA region (PD 56.6 ± 26.0%, Ctrl 83.8 ± 16.3%, 
P = 0.018), neurons of the putamen (PD 51.5 ± 29.0%, Ctrl 
85.4 ± 9.9%, P = 0.012), Purkinje cells of cerebellar cor-
tex (PD 44.0 ± 23.8%, Ctrl 89.2 ± 14.5%, P < 0.001), and 
principal neurons of the dentate nucleus (PD 44.0 ± 23.8%, 
Ctrl 94.6 ± 9.9%, P = 0.021) (Figs. 3 and 4a–e). A trend 
for lower complex I staining in PD was also seen in the 
principal neurons of the red nucleus (PD 58.6 ± 33.2%, 
Ctrl 91.7 ± 11.7%, P = 0.051) and the basis pontis (PD 
66.7 ± 36.6%, Ctrl 96.1 ± 3.8%, P = 0.088), although it did 
not reach statistical significance (Figs. 3 and 4f–g). In the 
SNc, there was a significantly higher number of complex 
I negative (PD 29.5 ± 23.6%, Ctrl 7.0 ± 6.1%, P = 0.036) 
and intermediate (PD 29.1 ± 10.8%, Ctrl 16.0 ± 6.68%, 
P = 0.019) neurons in PD compared to controls (Figs. 3 
and 4h). Individual results of the complex I analysis are 
summarized in Tables 2 and 3.
Decreased complex I staining was observed also diffusely 
in the neuropil, the dense network of neuronal processes 
(dendrites, axons, synapses) and glial cells surrounding 
neuronal somata. However, our method did not allow us to 
resolve and differentiate specific components of the neuropil 
for complex I quantification.
To confirm that the observed complex I deficiency was 
not due to an overall reduction of mitochondrial mass, 
we quantified the PFCA for complex II (PD 96.6 ± 6.0%, 
n  =  355, Ctrl 98.0  ±  2.3%, n  =  136), and porin (PD 
90.3 ± 10.1%, n = 232, Ctrl 87.3 ± 14.2%, n = 119) in 
sequential sections of the prefrontal cortex from all sam-
ples. PD and controls showed similar neuronal staining for 
complex II (P = 0.32) and porin (P = 0.41).
To further assess the functional impact of neuronal 
complex I reduction in the PD brain, we performed kinetic 
measurements of complex I enzymatic activity using fresh 
frozen brain tissue from the prefrontal cortex, putamen 
and cerebellum. Individuals with PD had a decreased ratio 
of complex I to citrate synthase activity in the prefrontal 
cortex (Ctrl 27.8 ± 7.6, PD 14.4 ± 4.9, P = 0.003) and 
putamen (Ctrl 12.2 ± 4.1, PD 7.6 ± 3.4, P = 0.036). While 
the decrease was not significant at the group level in the 
cerebellum (Ctrl 4.1 ± 2.4, PD 3.2 ± 1.9, P = 0.43), there 
was high interindividual variation with five of nine PD 
samples showing substantially lower activity compared to 
controls (Fig. 5a–c).
Native Western blot analysis in homogenized tissue also 
showed lower complex I quantity, both visually and densi-
tometrically in most PD samples. This difference was not 
statistically significant at the group level, however. Notably, 
large interindividual variability was seen in the PD group: 
prefrontal cortex batch 1 (85 ± 8% of Ctrl P = 0.252), pre-
frontal cortex batch II (87 ± 14% of Ctrl P = 0.429), stria-
tum (95 ± 41% of Ctrl P = 0.24) (Fig. 5d–k).
Complex I deficiency occurs independently 
of mtDNA changes
While all areas we examined showed neuronal complex 
I deficiency, only dopaminergic neurons of the SNc 
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Fig. 3  Widespread complex I deficiency in the PD brain. Repre-
sentative photographs of complex I IHC in individuals with PD and 
controls; a prefrontal cortex, b hippocampus, c putamen, d cerebel-
lar cortex, e dentate nucleus, f pons, g red nucleus, h SNc. Complex 
I deficiency is visually evident in all areas (except the basal pontine 
nuclei). Of note, decreased complex I staining in PD was observed 
not only in the neuronal somata, but also in the surrounding neuro-
pil. a–e Magnification ×400, scale bar 50 µm. h Magnification ×200, 
scale bar 100 µm
harbored significant mtDNA changes in PD in the form 
of higher deletion levels and wild-type mtDNA deple-
tion [13]. The remaining neuronal populations showed no 
significant mtDNA differences between PD and controls. 
Results from the hippocampus and putamen are shown in 
Fig. 6. Data from the SNc, frontal cortex and cerebellum 
from the same individuals have been reported previously 
[13].
418 Acta Neuropathologica (2018) 135:409–425
1 3
Fig. 4  Semiquantitative analyses of complex I deficiency in PD and 
control neurons. Individuals with PD show significantly decreased 
neuronal complex I PFCA in the prefrontal cortex (P  =  0.023) (a), 
hippocampus (P  =  0.018) (b), putamen (P  =  0.012) (c), cerebel-
lar cortex (P < 0.001) (d) and the dentate nucleus (P = 0.021) (e). 
There is also a clear trend towards lower complex I levels in the basal 
pontine nuclei (P = 0.088) (f) and the red nucleus (P = 0.051) (g), 
although not reaching statistical significance. The substantia nigra (h) 
was analysed visually. There is a significantly higher number of com-
plex I negative (P = 0.036) and intermediate (P = 0.019) neurons and 
lower number of complex I positive neurons (P = 0.008) in PD. Bars 
show mean with SD. PFCA positive fractional cytoplasmic area. ns 
non-significant
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Lewy pathology is less prevalent in complex I 
negative neurons
To test for a potential association between Lewy pathology 
and complex I deficiency, we performed double fluorescent 
immunohistochemistry for complex I and α-synuclein in the 
SNc (Fig. 7). Lewy pathology, including Lewy bodies, pale 
bodies and Lewy neurites, was found throughout the SNc 
of individuals with PD and was not present in the control. 
Lewy pathology was significantly less prevalent in complex I 
negative compared to complex I positive dopaminergic SNc 
neurons (P = 0.005, OR 0.24, 95% CI 0.09–0.69). The neu-
ronal counts are shown in Table 4.
Discussion
We show that mitochondrial complex I deficiency is not 
limited to the SNc and other areas affected by neurodegen-
eration, but is a widespread phenomenon affecting neurons 
throughout the brain of individuals with PD. Neuronal 
complex I is decreased both in areas universally affected 
Table 2  Quantitative 
assessment of neuronal complex 
I staining
The table shows the number of analysed neurons per individual (n) and mean PFCA value expressed as 
% ± SD
ID Prefrontal 
cortex
Hippocampus Putamen Red nucleus Basal nuclei 
of pons
Cerebellar 
cortex
Dentate 
nucleus
n PFCA n PFCA n PFCA n PFCA n PFCA n PFCA n PFCA
PD1 40 2 ± 3 74 6 ± 3 22 10 ± 7 8 0 ± 0 16 0 ± 0 13 0 ± 1 15 1 ± 1
PD2 43 6 ± 6 85 40 ± 19 18 82 ± 11 – – 19 0 ± 0 13 21 ± 13 14 18 ± 10
PD3 31 1 ± 1 64 75 ± 13 – – – – 21 9 ± 6 17 15 ± 16 10 20 ± 12
PD4 42 71 ± 22 119 39 ± 16 29 37 ± 9 7 73 ± 10 28 88 ± 8 13 65 ± 16 23 56 ± 19
PD5 50 52 ± 24 68 69 ± 13 15 36 ± 25 – – 23 67 ± 13 14 38 ± 10 11 74 ± 10
PD6 48 28 ± 14 60 68 ± 18 26 58 ± 19 9 39 ± 12 17 94 ± 3 15 70 ± 9 18 74 ± 12
PD7 40 89 ± 7 70 83 ± 9 22 88 ± 5 9 91 ± 8 15 98 ± 2 – – – –
PD8 – – 83 57 ± 22 13 92 ± 8 – – 20 72 ± 7 18 49 ± 21 15 31 ± 11
PD9 44 42 ± 21 95 63 ± 19 16 60 ± 18 – – 26 89 ± 8 17 48 ± 16 14 73 ± 13
PD10 36 81 ± 9 – – 11 52 ± 16 5 58 ± 16 – – 14 40 ± 11 13 65 ± 16
PD11 38 63 ± 17 52 52 ± 18 21 72 ± 6 7 96 ± 5 20 96 ± 3 14 61 ± 13 16 82 ± 9
PD12 42 77 ± 17 61 61 ± 17 21 71 ± 19 7 87 ± 12 20 95 ± 4 – – – –
PD13 49 86 ± 15 85 85 ± 10 22 74 ± 11 9 38 ± 10 19 76 ± 12 9 45 ± 22 11 60 ± 13
PD15 – – – – 15 60 ± 14 – – – – 16 58 ± 15 20 78 ± 7
PD16 – – – – 27 29 ± 13 – – – – 21 37 ± 12 22 42 ± 9
PD17 58 61 ± 18 – – – – – – – – – – – –
PD18 60 75 ± 13 – – – – – – – – 14 70 ± 5 16 91 ± 4
Ctrl1 46 93 ± 5 81 83 ± 15 23 2 ± 3 7 98 ± 2 – – 16 96 ± 5 – –
Ctrl2 46 71 ± 16 – – 23 2 ± 3 8 73 ± 20 – – 17 96 ± 5 – –
Ctrl3 40 95 ± 6 – – 16 2 ± 3 10 92 ± 5 16 97 ± 4 13 96 ± 7 – –
Ctrl4 52 89 ± 10 64 94 ± 7 25 2 ± 3 – – 20 97 ± 2 13 96 ± 4 11 92 ± 5
Ctrl5 38 80 ± 14 48 85 ± 8 20 2 ± 3 9 98 ± 2 23 96 ± 3 13 98 ± 1 13 98 ± 3
Ctrl6 42 75 ± 9 61 74 ± 17 – – – – 14 92 ± 5 15 60 ± 12 – –
Ctrl9 – – 58 83 ± 22 – – 9 95 ± 3 22 97 ± 2 15 84 ± 6 17 93 ± 14
Table 3  Visual evaluation of neuronal complex I staining in SN neu-
rons
Percentages of complex I negative, intermediate and positive neurons 
in the substantia nigra of patients and controls. Each number shows 
the mean ± SD of three visual analyses each by a different investiga-
tor (see “Materials and methods”)
ID % Neg % Int % Pos
PD1 77 ± 12 20 ± 10 3 ± 2
PD4 23 ± 4 46 ± 9 31 ± 6
PD6 45 ± 10 33 ± 5 22 ± 11
PD7 3 ± 1 15 ± 6 52 ± 4
PD10 27 ± 2 23 ± 2 52 ± 4
PD11 14 ± 2 27 ± 7 59 ± 5
PD12 3 ± 2 28 ± 8 69 ± 8
PD13 45 ± 11 41 ± 3 14 ± 9
Ctrl1 1 ± 1 10 ± 2 89 ± 2
Ctrl3 8 ± 3 16 ± 6 76 ± 8
Ctrl4 2 ± 1 5 ± 1 93 ± 2
Ctrl5 6 ± 3 25 ± 8 69 ± 7
Ctrl6 5 ± 2 18 ± 4 77 ± 6
Ctrl9 16 ± 7 21 ± 2 63 ± 6
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by neurodegeneration, such as the SNc, areas with mild 
and/or variable neuronal loss, like the hippocampus and 
prefrontal cortex, and even areas believed to remain unaf-
fected such as the cerebellar cortex and dentate nucleus 
[12]. Neuronal complex I deficiency appeared most pro-
nounced in the SNc, putamen and cerebellar cortex, and 
mildest in the basal pontine nuclei and red nucleus, but 
regional differences were generally minor and all eight 
brain regions we examined showed decreased complex 
I staining. While our measurements in the basal pontine 
nuclei and red nucleus did not reach statistical significance 
at the group level, mean complex I PFCA was substantially 
lower in PD and the lack of significance was attributed to 
interneuronal and interindividual variation. The remain-
ing respiratory complexes and porin showed no difference 
between PD and controls suggesting a selective reduction 
of complex I, rather than a general respiratory chain defect 
or decrease of total mitochondrial mass.
When interpreting our findings, it is important to be aware 
of the methodological limitations of IHC as a semiquantita-
tive method. Due to the fact that antigen–antibody reactions 
are non-stoichiometric and DAB-based staining intensity 
does not follow the Lambert–Beer law of light absorbance 
[42], the relationship between staining intensity and anti-
gen quantity is nonlinear. Therefore, direct measurement of 
staining intensity can lead to over- or under-estimation of 
Fig. 5  Reduced complex I activity in the PD brain. Complex I activ-
ity in homogenate from prefrontal cortex (a), striatum (b) and cer-
ebellum (c). Each individual with PD is shown against the mean of 
controls (Ctrl) with SD. There is a significant decrease of complex 
I activity in the frontal cortex (P = 0.003) and striatum (P = 0.036) 
of individuals with PD. The cerebellum shows no significant differ-
ence (P = 0.43), but with high variability in the PD group. Individu-
als with PD 7, 10, 12, 13 and 14 shows substantially lower complex 
I activity compared to controls. d–k Tissue homogenates from pre-
frontal cortex (d, f), striatum (e) and cerebellum (g) were separated 
by blue-native gel electrophoresis, followed by Western blotting and 
probing for complex I (CI) and complex II (CII). Prefrontal cortex 
was analysed in two batches (prefrontal I, II) to accommodate gel 
size. Densitometric analysis showed no significant difference between 
controls and PD at the group level in any of the examined regions. 
Prefrontal cortex batch I (P = 0.252) (h), prefrontal cortex batch II 
(P = 0.429) (i), striatum (P = 0.24) (j). Statistical analysis was not 
performed in the cerebellum due to a low number of controls (k)
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the actual difference in neuronal complex I content between 
samples. To address this limitation, we measured instead 
the fraction of cytoplasmic immunoreactivity for complex I, 
i.e. how much of the neuronal cytoplasm is at all stained for 
complex I (PFCA). The advantage of this approach is that 
it does not rely on direct quantification of pixel intensity. 
Instead, each cytoplasmic pixel is binarized into one of two 
possible states, stained or unstained, and the cytoplasmic 
fraction that stains positive compared to a negative control 
is calculated. Thus, while still semiquantitative, our method 
of PFCA quantification allows an objective and more pre-
cise relative quantification of neuronal complex I content 
between brain regions and individuals. A similar approach 
has been successfully used to assess the endosomal–lysoso-
mal system in prion disease [21].
The NDUFB8 subunit is essential for the assembly, struc-
ture stability and function of the complex [39, 46] and its 
knockdown decreases complex I activity in animals [10]. 
We, therefore, reasoned that NDUFB8 deficiency should 
reflect the entire complex. This was corroborated by activ-
ity measurements showing widespread functional complex 
I deficiency in the PD brain. While most individuals with 
PD had lower complex I activity in the cerebellum compared 
to controls, this difference was not significant at the group 
level due to large interindividual variation. This may be real 
biological variation, or a technical artefact reflecting the 
tissue architecture of the cerebellum. The ratio of Purkinje 
cells, which are the main complex I source in the cerebellar 
cortex, to other cell types and underlying white matter is 
susceptible to inter-sample variability due to the highly con-
voluted structure of the cerebellar surface and small number 
of Purkinje cells compared to other cell populations.
Western blot analysis showed a trend for lower complex I 
levels in PD, but this did not reach statistical significance at 
the group level. We believe this to be due to a combination 
of overall lower sensitivity of Western blotting, which only 
allows robust changes in protein quantity to be reliably quan-
tified and large interindividual variation. This discrepancy 
between Western blotting and other techniques of assessing 
the respiratory chain in PD has been reported previously 
[32]. Our IHC analyses suggest that neuronal complex I defi-
ciency is generally mild in PD and shows large interneuronal 
variability, which may be masked by studies in homogenized 
tissue. Thus, single cell analysis is a more reliable method 
for assessing complex I deficiency in PD.
Our findings appear to contradict studies showing normal 
complex I activity in homogenized tissue of the cerebel-
lum, striatum [18, 24, 25, 36] and frontal cortex [18, 36] in 
PD. This difference may be partly due to lower sensitivity 
of analyses in brain homogenate. We show that complex I 
levels in PD can vary greatly between neighboring neurons 
in the same individual (Fig. 4). This heterogeneity is not 
detectable in homogenized tissue and may create sampling 
bias contributing to the variable and contradictory results 
of previous studies. Our method of PFCA measurement cir-
cumvents this problem by assessing complex I at the level 
of individual neurons. Nevertheless, in our experiments, 
we detected lower complex I activity and a mild quantita-
tive reduction also in homogenized tissue. Therefore, while 
PFCA measurements appear to be more sensitive, this is not 
sufficient to explain the negative findings of other studies. 
Sample heterogeneity may also play a role. Previous stud-
ies were based on material from brain banks, which may be 
subject to selection bias (i.e. not entirely population-based) 
and are commonly not accompanied by systematically col-
lected prospective clinical information. Pathology alone is 
not always sufficient to distinguish PD from other synucle-
inopathies and previous research suggests that complex I 
Fig. 6  Neuronal complex I deficiency does not correlate with 
mtDNA damage in hippocampus and putamen. Scatter plot show-
ing mtDNA copy number (a, b) and deletion levels (c, d) in single 
neurons from the putamen and hippocampus. There is no significant 
difference between controls and individuals with PD for mtDNA 
copy number or deletion levels in the putamen (Ctrl 15,204 ± 6736, 
PD 15,927  ±  7453 mtDNA copies/neuron, P  =  0.551; Ctrl 
19.40 ± 5.80%, PD 17.87 ± 7.28% deleted mtDNA, P = 0.178), or 
hippocampus (Ctrl 14,770 ± 6118, PD 16,990 ± 7079 mtDNA cop-
ies/neuron, P  =  0.140; Ctrl 14.69  ±  5.52%, PD 12.91  ±  4.31% 
deleted mtDNA, P = 0.107). Bars show mean and SD
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may be intact in other parkinsonisms [36]. Our sample is 
from an entirely population-based, longitudinally followed 
cohort, which has been extensively characterized clinically, 
pathologically and genetically, and is, therefore, by current 
standards as close as possible to true idiopathic PD.
Our findings do not corroborate the current hypoth-
esis that complex I deficiency in PD may be the result of 
accumulating deletions and quantitative depletion of the 
mtDNA [4, 16]. Moreover, ultra-deep-sequencing stud-
ies in single neurons and brain homogenates have shown 
no difference in the point mutational burden of mtDNA-
encoded complex I genes between PD individuals and 
Fig. 7  Lewy pathology is less 
common in complex I negative 
neurons. Representative neurons 
from the SNc of individuals 
with PD: complex I positive 
without Lewy pathology (a); 
complex I negative without 
Lewy pathology (b); complex I 
positive with Lewy pathology 
(c); complex I negative with 
Lewy pathology (d). Sections 
have been stained for complex 
I subunit NDUFS1 (green), 
alpha-synuclein (red) and the 
nuclear marker DAPI (blue). 
Nuclei (#) and somata have 
been outlined (dotted line) in 
the merged images. Neuromela-
nin (*) and Lewy pathology 
(arrowhead) have been labelled. 
Scale bar: 15 µm
Table 4  Association between Lewy pathology and complex I
Counts of dopaminergic SNc neurons classified according to complex 
I status (columns) and Lewy pathology (rows). A total of 123 neurons 
from four individuals were evaluated. Columns show the number and 
fraction (%) of complex I positive and negative neurons containing 
Lewy pathology
Complex I
Positive Negative
Lewy pathology negative 52 (65%) 38 (88.4%)
Lewy pathology positive 28 (35%) 5 (11.6%)
Total 80 (100%) 43 (100%)
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controls, suggesting that mtDNA point mutations do not 
contribute to the observed complex I deficiency [8, 13]. 
Here, we show that complex I deficiency occurs in neurons 
from at least eight different brain areas in PD, whereas 
levels of mtDNA damage only exceed those of controls in 
the SNc. In fact, we found substantial complex I deficiency 
even in areas with very low levels of mtDNA damage such 
as the prefrontal cortex and cerebellum. Moreover, com-
plex I deficiency in PD has been reported in tissues with 
minimal or no mtDNA damage burden such as skeletal 
muscle, platelets and lymphocytes [3, 7, 27]. Collectively, 
these findings suggest that, contrary to dominant theory, 
neuronal complex I deficiency in PD can occur indepen-
dently of mtDNA damage.
Interestingly, we found that Lewy pathology is sig-
nificantly less prevalent in complex I negative neurons of 
the SNc. This is in line with a previous report showing 
α-synuclein pathology only in neurons with high levels of 
mitochondrial respiratory subunits [31]. These results do 
not support a causal link between complex I deficiency and 
α-synuclein pathology. The reason for the inverse associa-
tion of these two phenomena remains, however, unknown. 
One possibility is that neurons containing both pathologies 
(i.e. complex I deficiency and Lewy pathology) suffer a 
double-insult and have a short lifespan, thus being unlikely 
to detect by pathology at end-stage. Alternatively, it could be 
speculated that intact complex I activity is required for Lewy 
body formation, at least in the initial phase of aggregation.
In spite of its widespread distribution, neuronal complex 
I deficiency does not follow the anatomical distribution of 
neurodegeneration or mitochondrial DNA damage. These 
findings do not support a direct link between complex I dys-
function and neuronal loss in PD. It is plausible that complex 
I deficiency is only one of multiple hits required to trigger 
neuronal death in PD. Another, more intriguing possibility is 
that complex I is actively downregulated as a compensatory 
response to moderate excess generation of reactive oxygen 
species (ROS). Evidence of increased oxidative damage has 
been consistently found in the PD brain [1, 45] and it has 
been shown that, under certain conditions, complex I inhibi-
tion [28] or modulation [29] can substantially decrease ROS 
generation. Irrespective of whether it is a pathogenic event 
or compensatory response, the extent of neuronal complex 
I deficiency in PD suggests that it is an important and inher-
ent part of the disorder. We, therefore, believe that further 
elucidating this phenomenon will be key to understanding 
the pathogenesis of PD.
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